New Rx Shows Promise for Pulmonary Hypertension
New Rx Shows Promise for Pulmonary Hypertension
http://www.rxwiki.com/news-article/se…
Pulmonary arterial hypertension (PAH) can make everyday activities difficult. But a new treatment may be on the horizon.
Only days after selexipag (brand name Uptravi) got approval from the US Food and Drug Administration (FDA), a new study was published showing the drug’s potential for treating PAH. This study found that selexipag successfully cut the rates of hospitalization and worsening symptoms among PAH patients by 40 percent compared to placebo.
Actelion Pharmaceuticals, the maker of selexipag, said the drug is expected to become available to patients in the US in early January 2016.
Content
2.889 -> Pulmonary arterial hypertension (PAH) can
make everyday activities difficult.
8.28 -> But a new treatment may be on the horizon.
10.65 -> I'm Shelby Cullinan with your latest health
news.
13.47 -> Only days after selexipag got approval from
the FDA, a new study was published showing
18.86 -> the drug's potential for treating PAH.
21.849 -> This study found that selexipag successfully
cut the rates of hospitalization and worsening
27.279 -> symptoms among PAH patients by 40 percent
compared to placebo.
32.119 -> PAH is a condition marked by abnormally high
blood pressure in the blood vessel that carries
37.579 -> blood from the heart to the lungs.
40.37 -> Selexipag works to target a known disease
pathway that opens blood vessels to the lungs
44.829 -> and improves heart function.
46.82 -> This treatment is easier to use than other
PAH treatments delivered by infusion or injection.
52.6 -> Ask your doctor about newly approved medications.
Source: https://www.youtube.com/watch?v=QWm24m7bq1c